Key result
Biomarkers like troponin and BNP identify asymptomatic organ damage and predict adverse outcomes in hypertension.
Why the study?
Despite effective treatments, roughly 720 million people do not receive optimal hypertension management, prompting interest in whether biomarkers can identify asymptomatic organ damage and guide treatment.
Can biomarkers help guide therapy intensity and choice in individuals with hypertension?
Can biomarkers help guide therapy intensity and choice in individuals with hypertension?
Biomarkers may help identify higher-risk hypertensive patients who would benefit most from therapy, though their role in directly guiding treatment decisions requires further study.
May aid risk stratification in hypertension; leaves open whether biomarkers should guide therapy intensity or choice.
PURPOSE OF REVIEW: Approximately 1.28 billion people are affected by hypertension globally and the incidence of hypertension is on an upward trajectory with an aging population and increasing burden of risk factors including obesity. Despite low-cost, highly-effectively, easy-to-treat strategies, it is estimated that ∼720 million people are not receiving the treatment they need for optimal hypertension management. Several factors contribute to this including an unwillingness to be treated for an asymptomatic condition. RECENT FINDINGS: Biomarkers such as troponin, B-type Natriuretic Peptide (BNP), N-terminal-pro hormone BNP (NT-proBNP), uric acid, microalbuminuria have been found to be associated with adverse clinical outcomes among individuals with hypertension. Biomarkers also allow for identification of asymptomatic organ damage. SUMMARY: Biomarkers have the ability to identify higher risk individuals in whom risk-benefit for therapies may be most favorable, helping optimize the net benefit of therapy. Whether biomarkers can help guide therapy intensity and choice remains to be tested.
No takes yet. Share an insight, caveat, or question.
Kotta et al. (2023) conducted a review in Hypertension. Biomarker guided management was evaluated. Biomarkers including troponin, BNP, NT-proBNP, uric acid, and microalbuminuria are associated with adverse clinical outcomes and can identify asymptomatic organ damage in patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: